Market Overview

UPDATE: Jefferies Raises PT on Merck & Co. on Positive Outlook

Related MRK
MITICURE for house Dust Mite Allergic Rhinitis Now Available in Japan
Benzinga's Top Initiations
Novo Nordisk's First Diabetes Pill Could Be A $10-20B Super-Blockbuster (Seeking Alpha)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Hold rating on Merck & Co. (NYSE: MRK), and raised the price target from $46.00 to $48.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Merck & Co. closed on Tuesday at $45.51.

Latest Ratings for MRK

Nov 2015BerenbergInitiates Coverage onBuy
Sep 2015JP MorganMaintainsOverweight
Aug 2015JefferiesMaintainsHold

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings


Related Articles (MRK)

View Comments and Join the Discussion!

Get Benzinga's Newsletters